Analysed ELICIO THERAPEUTICS INC (ELTX:NASDAQ) News Sources
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P Study and Outlines Refined Phase 3 Development Strategy for ELI-002 7P in Adjuvant Pancreatic Cancer
15-06-2026
yahoo.com
Elicio Therapeutics Reports Multiple Complete Responses After ELI-002 7P Treatment and Subsequent Therapy with Checkpoint Inhibition in Metastatic mKRAS Pancreatic Cancer
17-06-2026
yahoo.com
Elicio Therapeutics Announces Pricing of $15 Million Registered Direct Offering
02-07-2026
yahoo.com
Elicio Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference
24-08-2026
yahoo.com
Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference
31-08-2026
yahoo.com
Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026
24-09-2026
yahoo.com
Elicio Therapeutics Presents Late-Breaking Phase 2 AMPLIFY-7P Results at ESMO Congress 2026 and Announces Simultaneous Publication in Nature Medicine
23-10-2026
yahoo.com
What is the current price of ELICIO THERAPEUTICS INC (ELTX:NASDAQ)?
The current price of ELICIO THERAPEUTICS INC (ELTX:NASDAQ) is $1.68.
ELICIO THERAPEUTICS INC (ELTX:NASDAQ) absolute price change since previous trading day?
The absolute price change of ELICIO THERAPEUTICS INC (ELTX:NASDAQ) since the previous trading day is $-0.07.
ELICIO THERAPEUTICS INC (ELTX:NASDAQ) percentage price change since previous trading day?
The percentage price change of ELICIO THERAPEUTICS INC (ELTX:NASDAQ) since the previous trading day is -4%.
What is the most recent average sentiment score for ELICIO THERAPEUTICS INC (ELTX:NASDAQ)?
The most recent average sentiment score for ELICIO THERAPEUTICS INC (ELTX:NASDAQ) is 71 out of 100.
What is the most recent average sentiment for ELICIO THERAPEUTICS INC (ELTX:NASDAQ)?
The most recent sentiment for ELICIO THERAPEUTICS INC (ELTX:NASDAQ) is .
SEC-8K** Filing Available For ELICIO THERAPEUTICS INC (ELTX:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.